Partnership also includes an agreement for Arvinas to sell its preclinical AR-V7 program to Novartis.
Novartis, Arvinas Agree to Strategic Collaboration to Develop Treatment for Prostate Cancer
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours